Distinction between bacterial and viral infections by serum measurement of human neutrophil lipocalin (HNL) and the impact of antibody selection

Journal of Immunological Methods
Zhang YuPer Venge

Abstract

The distinction between acute infections of bacterial or viral causes is clinically important, but often very difficult even for experienced doctors. Previous studies indicated that serum measurements of HNL (Human Neutrophil Lipocalin) might be a superior diagnostic means in this regard, but also indicated that the antibody conformation of the HNL assay might have an impact on the diagnostic performance. The aim of the present report was to examine this further. Several different (n=24) HNL ELISA assays were developed using different combinations of monoclonal and polyclonal HNL antibodies. Sera were collected from healthy persons (n=188) and from 155 patients with acute infections before any antibiotics treatment. The patients were diagnosed as having bacterial (n=69) or viral causes (n=86) of their infections. Plasma and serum were also examined by Western blotting using HNL-specific polyclonal antibodies. The optimal assay format for the distinction between bacterial and viral infection resulted in an area under the receiver operating characteristics curve (AuROC) for S-HNL of 0.98. (95% CI 0.94-1.00) as compared to 0.83 (0.76-0.88) for blood neutrophil counts and 0.69 (0.61-0.76) for S-CRP. Results also showed that differe...Continue Reading

References

Apr 1, 1995·Scandinavian Journal of Clinical and Laboratory Investigation·S Y XuP Venge
Aug 1, 1994·Scandinavian Journal of Clinical and Laboratory Investigation·S Y XuP Venge
Nov 4, 2000·Biochimica Et Biophysica Acta·S Xu, P Venge
Apr 14, 2009·Clinica Chimica Acta; International Journal of Clinical Chemistry·Linjun CaiPer Venge
Apr 17, 2010·Intensive Care Medicine·Johan MårtenssonClaes-Roland Martling
Sep 11, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Linjun CaiShengyuan Xu
May 23, 2012·Clinica Chimica Acta; International Journal of Clinical Chemistry·Johan MårtenssonPer Venge
Nov 21, 2013·The Lancet Infectious Diseases·Ramanan LaxminarayanOtto Cars
Oct 2, 2014·The New England Journal of Medicine·Carl Nathan, Otto Cars

❮ Previous
Next ❯

Citations

Feb 24, 2018·Upsala Journal of Medical Sciences·Per Venge
Apr 28, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Liat Ashkenazi-HoffnungOded Scheuerman
Oct 23, 2019·The Journal of Applied Laboratory Medicine·Per Venge, Shengyuan Xu
Feb 22, 2021·The Journal of Infection·B Leticia Fernandez-CarballoSabine Dittrich
Oct 24, 2020·Clinical and Experimental Pediatrics·Ji Hyun MoonHyung Eun Yim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.